Cardiovascular Disease Risk Factor
14
6
7
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 14 trials
100.0%
+13.4% vs benchmark
7%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (14)
Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
CARAMEL Observational Study
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases
Vitalis Cardio Pilot
Assessment and Prediction of Cardiovascular Health and Disease Risk Using Wearable Biometrics.
THE EFFECT OF ENDODONTIC TREATMENT ON CARDIOVASCULAR RISK BIOMARKERS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway
The Mauritius and Rodrigues Non-Communicable Disease (NCD) Study
Acute Postprandial Effects of Functional Ice Cream With Cimarrón Bean Extrudate in Adults
Weight Stigma in Women Who Are Obese: Assessing How an Acute Exposure to Stigma Negatively Impacts Cardiovascular Health